Nanotechnology×Immunology

The Frontier Brief for this collision is still being written. The evidence below already reflects the current model run.

Pre-company space. No named players have staked this collision yet — an emerging pairing where the field, not a firm, is the story so far.

35 researchers publish on both sides of this collision without the fields themselves having met. Every name below is counted from papers in the corpus — not inferred.

• Peter J. PetersRadboud Institute for Molecular Life Sciences
  3/1
• Yaqing WangUniversity of Hong Kong
  2/1
• Adam R. AbateWhitehead Institute for Biomedical Research
  2/1
• Raimond B. G. RavelliHartwig Medical Foundation
  2/1
• George CoukosFred Hutch Cancer Center
  1/2
• Núria MontserratHospital General Universitario Gregorio Marañón
  1/1
• Elena GarretaHospital General Universitario Gregorio Marañón
  1/1
• Drew WeissmanCalifornia Institute for Regenerative Medicine
  1/1
• Patricia PradoHospital General Universitario Gregorio Marañón
  1/1
• Yixuan WangGyeongsang National University
  1/1

• Harvard UniversityUS
  352/75
• Massachusetts Institute of TechnologyUS
  378/32
• Stanford UniversityUS
  360/30
• Chinese Academy of SciencesCN
  524/15
• University of PennsylvaniaUS
  146/42
• University of CambridgeGB
  200/24

• Macrophages in immunoregulation and therapeutics2023 · 2,150 citations · DOI ↗
  2
• The biology and function of exosomes in cancer2016 · 1,915 citations · DOI ↗
  2
• TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis2019 · 1,166 citations · DOI ↗
  2
• Towards personalized, tumour-specific, therapeutic vaccines for cancer2017 · 1,068 citations · DOI ↗
  2

Counted from the corpus. Institution counts use best-effort affiliation (every author on a paper is paired with every institution on it), so read them as presence, not headcount.